Author Interviews, Cancer Research, HPV / 13.06.2025

MedicalResearch.com Interview with: [caption id="attachment_69031" align="alignleft" width="150"]Pragati Advani MD, MPH, DrPHAssistant Professor of Oncology, Department of Thoracic Surgery And on faculty with the Department of Cancer Prevention and Population Sciences Roswell Park Comprehensive Cancer Center Buffalo, NY Dr. Advani[/caption] Pragati Advani MD, MPH, DrPH Assistant Professor of Oncology, Department of Thoracic Surgery And on faculty with the Department of Cancer Prevention and Population Sciences Roswell Park Comprehensive Cancer Center Buffalo, NY MedicalResearch.com: What is the background for this study? Response: In oncology, a study of second primary malignancy (SPM) is an emerging field that is predominantly driven by our success in identifying and treating the first primary cancers (FPCs). HPV is responsible for nearly a third of all infectious agent-related FPCs (including cancer of the oropharynx, anus, vulva, vagina, cervix and penis). Advances in diagnostic and treatment methods have resulted in improved survivorship among these patients. However, they remain at risk for developing a SPM. No studies thus far had examined the risk of SPMs after HPV-associated FPCs, stratified by cancer site and gender.
Author Interviews, Cancer Research, Colon Cancer, Gastrointestinal Disease, HPV / 07.05.2025

MedicalResearch.com Interview with: [caption id="attachment_68399" align="alignleft" width="150"]Ashley Robinson, MD, lead authorSecond-year internal medicine resident Advocate Lutheran General Hospital Dr. Robinson[/caption] Ashley Robinson, MD, lead author Second-year internal medicine resident Advocate Lutheran General Hospital MedicalResearch.com: What is the background for this study? Response: Briefly, anal cancer makes up around 1% of gastrointestinal cancers and more than 90% of all anal cancers are caused by chronic human papillomavirus or HPV infections. In previous research, it has been noted that women over the age of 65 have rates that were increasing more than other groups and myself along with my colleagues and the principal investigator of this project, Dr. Eli Ehrenpreis, wanted to further characterize these findings, looking into more specific details of these previously noted trends. Using data from a public database ran by the National Cancer Institute called the Surveillance, Epidemiology and End Results program, also known as SEER, and their statistical analysis software, SEER*Stat, we analyzed anal cancer incidence trends, looking at differences between sex, age, and ethnicity in order to further identify specific groups that have more rapidly increasing rates than others.
Author Interviews, COVID -19 Coronavirus, Herpes Viruses, HIV, HPV, Infections, STD / 24.04.2023

MedicalResearch.com Interview with: [caption id="attachment_60333" align="alignleft" width="146"]Manoj Gandhi, MD PhDSenior Medical Director of Genetic Testing Services, Thermo Fisher Scientific. Dr. Gandhi[/caption] Manoj Gandhi, MD PhD Senior Medical Director of Genetic Testing Services, Thermo Fisher Scientific. Dr. Gandhi has been working to advance the quality of medical care globally. Using his knowledge of Clinical Medicine and Molecular Biology/Pathology, he is focused on bridging these two fields and bringing innovative solutions that help advance science, the practice of medicine with the ultimate goal of impacting patient lives, whether it be in Infectious Diseases or Oncology or Personalized Medicine. This approach allows him to explore creative ways to utilize technology to help better identify diseases and improve the direction and value of treatment. MedicalResearch.com: What are the most common STIs prevalent in the US and worldwide today? Response: By far, the most common STIs in the US and worldwide is Human Papillomavirus (HPV) that can cause cervical cancer in women and Herpes Simplex Virus (HSV) that is the cause of genital herpes. Outside of these two major causes of STI, the others that are very common are Chlamydia, Gonorrhea, Trichomoniasis and Syphilis. It is important to note that the reported cases represent only a subset of the individuals with an infection as many may be asymptomatic and could be spreading these STIs to others. HIV is another STI that is common but usually rests in its own category due to its impact.
Author Interviews, HPV, JAMA, Vaccine Studies / 01.11.2022

MedicalResearch.com Interview with: [caption id="attachment_59684" align="alignleft" width="150"]Dr. Didem Egemen PhD Statistician, Division of Cancer Epidemiology & Genetics National Cancer Institute Dr. Egemen[/caption] Dr. Didem Egemen PhD Statistician, Division of Cancer Epidemiology & Genetics National Cancer Institute MedicalResearch.com: What is the background for this study? Response: Persistent infection with human papillomavirus (HPV), a sexually transmitted disease, is the cause of virtually all cervical cancers. Various studies have reported high effectiveness of HPV vaccination in preventing HPV infection and cervical cancer, particularly when administered at early ages. In this study, we looked at the proportion of females eligible for vaccination (<26 years of age in 2006 when the vaccine was FDA approved) who were unvaccinated, vaccinated against HPV before sexual debut, and vaccinated after debut. Then we estimated the prevalence of HPV 16 and 18, the two HPV genotypes that cause most cervical cancers, in each subset.
Author Interviews, Cancer Research, HPV / 17.12.2021

MedicalResearch.com Interview with: [caption id="attachment_58558" align="alignleft" width="176"]Ashish A. Deshmukh, PhD, MPH Associate Professor, Management, Policy & Community Health Associate Director, Center for Health Services Research Co-director, Clinical Analytics and Decision Science Lab UTHealth School of Public Health Houston, TX 77030 Dr. Deshmukh[/caption] Ashish A. Deshmukh, PhD, MPH Associate Professor, Management, Policy & Community Health Associate Director, Center for Health Services Research Co-director, Clinical Analytics and Decision Science Lab UTHealth School of Public Health Houston, TX 77030 MedicalResearch.com: What is the background for this study? Response: Oropharyngeal cancer is the most common cancer caused by human papillomavirus (HPV) in the United States (US). We know from previous studies that oropharyngeal cancer to be one of the fastest rising cancers in the US. However, trends (i.e., extent of change) in incidence rates among men and women in all 50 US states and trends according to tumor diagnostic characteristics (i.e., stage, size) have not been comprehensively studied. In addition, no prior study evaluated contemporary trends in oropharyngeal cancer mortality (death) rates in the US. Our study provides a comprehensive picture of oropharyngeal cancer incidence and mortality (according to age, stage, tumor size, and state of residence) in all 50 states and DC.
Author Interviews, HPV, Vaccine Studies / 01.10.2021

MedicalResearch.com Interview with: [caption id="attachment_58184" align="alignleft" width="150"]Holly Frost, MD Assistant Professor Pediatrics University of Colorado Anschutz School of Medicine Dr. Frost[/caption] Holly Frost, MD Assistant Professor Pediatrics University of Colorado Anschutz School of Medicine [caption id="attachment_58185" align="alignleft" width="150"] Dr. Sebastian[/caption] Thersia Sebastian, MD Pediatrics, Denver Health  MedicalResearch.com: What is the background for this study? Response: Among children with acute otitis media (AOM) S.pneumoniae, H.influenzae, and M.catarrhalis are the predominant bacterial otopathogens. Historically, the gold standard for diagnosing otopathogens has been through middle ear fluid (MEF) culture. The challenge with MEF culture is that it is time-consuming and requires expert training often only done by specialists, thereby limiting its diagnostic utility to guide routine clinical care. Recent studies have shown that there is a high correlation between nasopharyngeal (NP) and MEF organisms during AOM. It is easier to collect NP swabs and less training is required. Thus, NP samples could serve as a surrogate for detection of otopathogens, potentially making identification of otopathogens practical and feasible in a typical practice environment compared to a MEF collection. Identification of otopathogens could be critical in treatment management of AOM, especially in the era of antimicrobial stewardship efforts to overall reduce unnecessary antibiotic use. Our goal was to compare the sensitivity and specificity of NP PCR to NP culture for common bacteria that cause ear infections. 
Author Interviews, CDC, HPV, JAMA, Vaccine Studies / 17.09.2021

MedicalResearch.com Interview with: [caption id="attachment_58124" align="alignleft" width="133"] Dr. Sonawane[/caption] Kalyani Sonawane, PhD Assistant Professor of Management, Policy and Community Health UTHealth School of Public Health in Houston MedicalResearch.com: What is the background for this study? Response: Safety concern regarding the HPV vaccine is one of the most significant barriers to vaccination. Our objective was to determine how many US adolescents did not initiate the HPV vaccine during 2015-2018 because their parents had concerns regarding the vaccine’s safety. We also analyzed vaccine adverse event reporting data, in parallel, to understand if the public sentiment of HPV vaccine safety is in alignment with evidence from the vaccine safety surveillance system. 
Author Interviews, HPV, JAMA, OBGYNE / 16.09.2021

MedicalResearch.com Interview with: Helen Trottier Ph.D Assistant Professor, Department of Social and Preventive Medicine, Researcher, CHU Sainte-Justine Research Center Université de Montréal Montréal, Québec, Canada MedicalResearch.com: What is the background for this study? Response: We know that HPV infection can have serious consequences such as the development of cancerous lesions in the cervix. HPV infection is also very prevalent in young women of childbearing age but the possible consequences of HPV in pregnancy have been poorly studied. Some population registers around the world have shown a reduction in the risk of preterm birth with HPV mass vaccination, but we must be careful with this kind of ecological correlation. We have set up a large cohort study in pregnant women to study the association between HPV in pregnancy and preterm birth by targeting certain HPV genotypes and the duration of the infection.
Author Interviews, Cancer Research, HPV, JAMA, Vaccine Studies / 07.09.2021

MedicalResearch.com Interview with: [caption id="attachment_58056" align="alignleft" width="200"]Yuehan (Jenny) Zhang, ScM PhD Candidate in Cancer Epidemiology Johns Hopkins Bloomberg School of Public Health Yuehan Zhang[/caption] Yuehan (Jenny) Zhang, ScM PhD Candidate in Cancer Epidemiology Johns Hopkins Bloomberg School of Public Health MedicalResearch.com: What is the background for this study? Response: Human Papillomavirus (HPV) is the most common sexually transmitted infectious virus worldwide. Oral HPV infection has resulted in a continual increase in the incidence of oropharynx cancer over the past two decades in the US. New HPV infections are preventable with vaccines, which first entered use in the US in 2006.
Author Interviews, Cancer Research, Gender Differences, HPV, JAMA, Vaccine Studies / 27.04.2021

MedicalResearch.com Interview with: Michelle M. Chen, MD/MHS Clinical Lecturer Department of Otolaryngology-Head and Neck Surgery University of Michigan MedicalResearch.com: What is the background for this study? Response: HPV is the most common sexually transmitted infection in the United States and associated with several malignancies including oropharyngeal, cervical, vaginal, vulvar, penile, and anal cancers. In 2020, the FDA expanded the indications for HPV vaccination to include the prevention of oropharyngeal cancer, which is the most common HPV-associated malignancy and about 80% of oropharyngeal cancer patients are male. HPV vaccination rates are closely tracked for adolescents but less is known about vaccination rates for young adults. The goal of our study was to understand HPV vaccinations for young adult men and women, ages 18-21. 
Author Interviews, Cancer Research, HPV, Karolinski Institute, NEJM, Vaccine Studies / 30.09.2020

MedicalResearch.com Interview with: Dr. Jiayao Lei PhD Prof. Pär Sparén PhD Karolinski Institute MedicalResearch.com: What is the background for this study? Response: The efficacy and effectiveness of quadrivalent HPV (qHPV) vaccine protecting against HPV infection, genital warts and high-grade precancerous cervical lesions have been shown. However, there is lack of population-based studies in examining the association between HPV vaccine and invasive cervical cancer on individual level. 
Author Interviews, Dermatology, HPV, Infections, JAMA, OBGYNE / 08.01.2020

MedicalResearch.com Interview with: Niklas Worm Andersson, MD Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen NV, Denmark MedicalResearch.com: What is the background for this study? What is Podophyllotoxin used for? Response: Podophyllotoxin is an antimitotic agent primarily used in the local treatment of anogenital warts, which are among the most prevalent sexually transmitted diseases worldwide. Most women affected by anogenital warts are of childbearing age and during pregnancy, they may become symptomatic, enlarge, or multiply. While podophyllotoxin is part of first-line treatment of anogenital warts for the non-pregnant population, it is contraindicated during pregnancy. Fetal safety data are limited and to our knowledge, no previous human data exist to help inform on this issue.
Author Interviews, Cancer Research, HPV / 20.11.2019

MedicalResearch.com Interview with: [caption id="attachment_52225" align="alignleft" width="133"]Ashish Deshmukh, PhD, MPH Assistant Professor UTHealth School of Public Health Houston Dr. Deshmukh[/caption] Ashish Deshmukh, PhD, MPH Assistant Professor UTHealth School of Public Health Houston MedicalResearch.com: What is the background for this study? Response: Anal cancer is one of the six human papillomavirus associated cancers.  Rates of anal cancer are increasing in the US, but no prior study quantified the contemporary trends (i.e., increase in rates over time) in anal cancer incidence. It was unknown whether the rise is real or driven by increased screening in some high-risk populations. Incidence trends according to age and stage at diagnosis was also never comprehensively studied. Furthermore, it was unknown whether the rise in incidence has led to a rise in mortality. Our objective was to answer these questions.
Author Interviews, Cancer Research, HPV, JAMA, OBGYNE / 07.11.2019

MedicalResearch.com Interview with: Rachel L. Winer, PhD Professor Department of Epidemiology School of Public Health HPV Research Group University of Washington Seattle, WARachel L. Winer, PhD Professor Department of Epidemiology School of Public Health HPV Research Group University of Washington Seattle, WA  MedicalResearch.com: What is the background for this study? Response: In the U.S., 25% of women do not receive recommended cervical cancer screening. Increasing screening participation is a high priority, because over half of the 12,000 cervical cancers diagnosed each year in the U.S. are in women who are underscreened. Currently available options for cervical cancer screening in the U.S. include Pap testing or HPV testing, either alone or in combination. HPV self-sampling is an emerging option for screening because HPV tests – unlike Pap tests – can be performed on either clinician- or self-collected samples, with similar accuracy. Internationally, several countries (including Australia and the Netherlands) include HPV self-sampling as a cervical cancer screening option for underscreened women. 
Author Interviews, Gender Differences, HPV / 16.09.2019

MedicalResearch.com Interview with: [caption id="attachment_51273" align="alignleft" width="149"]Dr. Ashish A. Deshmukh UT Health School of Public Health Houston Dr. Deshmukh[/caption] Dr. Ashish A. Deshmukh UT Health School of Public Health Houston MedicalResearch.com: What is the background for this study? Response: The HPV vaccination is recommended for females and males for prevention of 6 cancers (cervical, oropharyngeal, anal, penile, vaginal, and vulvar). Nearly 43,000 HPV-associated cancer cases are diagnosed every year in the US. Yet, it is extremely unfortunate and something that continues to bother us that HPV vaccination coverage remains low (50% in 2018) in the US and completion rate is nearly 5% lower in boys. Different from some industrialized nations where vaccination policy is school-based, vaccination policy in the US is clinic-based and parents are generally responsible for making vaccination decisions for their children. Generally, there are two main factors that drive parents’ decision-making: (1) how much knowledge they have of HPV and (2) recommendation from a healthcare professional. We analyzed the National Cancer Institute’s Health Information National Trend Survey (HINTS) of over 6000 participants focusing on their knowledge of HPV and HPV vaccination and whether participants received any vaccination recommendation from their health care provider. 
Author Interviews, Cancer Research, HPV, OBGYNE / 15.08.2019

MedicalResearch.com Interview with: [caption id="attachment_50822" align="alignleft" width="199"]Marc Eloit, D.V.M, Ph.D. Pathogen Discovery Laboratory, Biology of Infection Unit, Institut Pasteur Paris, France Dr. Eloit[/caption] Marc Eloit, D.V.M, Ph.D. Pathogen Discovery Laboratory, Biology of Infection Unit, Institut Pasteur Paris, France MedicalResearch.com: What is the background for this study? Response: Human papillomaviruses (HPV) are responsible for >99% of cervical cancers. Currently, cervical cancer screening either focuses on testing for the presence of HPV or identifying abnormal cervical cells with cytology (Pap test). However, molecular diagnostic tests based on the detection of viral DNA or RNA have low positive predictive values for the identification of cancer or precancerous lesions, and analysis of cervical cells with the Pap test, even when combined with molecular detection of high-risk HPV, results in a significant number of unnecessary colposcopies. We have developed HPV RNA-Seq, a new “two-for-one” molecular diagnostic test that not only detects the type of HPV, but also identifies precancerous markers. This test is therefore designed to diagnose the riskiest forms of HPV infection, provide rapid results at moderate cost, and helps avoiding unnecessary diagnostic procedures. HPV RNA-Seq is based on the dual combination of multiplexed reverse transcription PCR (RT-PCR) and next-generation sequencing (NGS). RT-PCR is a sensitive way to detect small amounts of RNA, the genetic material that reflects the activity of the HPV genes, and NGS finely characterizes the amplified viral sequences. This enables detection of up to 16 high-risk or putative high-risk HPV in a sample as well as the presence of precancerous markers.
Author Interviews, HPV, OBGYNE, Vaccine Studies / 24.06.2019

MedicalResearch.com Interview with: “Syringe and Vaccine” by NIAID is licensed under CC BY 2.0Ali Moghtaderi PhD MBA Assistant Research Professor and Avi Dor PhD Professor of Health Policy and Economics Milken Institute School of Public Health George Washington University MedicalResearch.com: What is the background for this study? Response: In this study, we investigate the effect of Human Papillomavirus (HPV) vaccination on participation in Pap test, which is one of the most effective cancer screening interventions. Cervical cancers are causally linked to HPV infections. The Pap test is a diagnostic procedure for early detection of cervical cancer. HPV vaccination provides partial protection against cervical cancer, and the Pap test is strongly recommended for women 21 to 65 years of age even after vaccination. If vaccination leads to a reduction in testing participation, it could contribute to greater incidence and severity of cervical cancer. Note that we focus on relatively older women (age 22 or older) who were not vaccinated at younger ages. 
Author Interviews, Dermatology, HPV, Yale / 20.06.2019

MedicalResearch.com Interview with: [caption id="attachment_49877" align="alignleft" width="160"]Richard J. Antaya, MD, FAAD, FAAP Professor, Dermatology and Pediatrics Yale University School of Medicine Dr. Antaya[/caption] Richard J. Antaya, MD, FAAD, FAAP Professor, Dermatology and Pediatrics Yale University School of Medicine  MedicalResearch.com: What is the background for this study? Response: Localized hyperthermia has been reported to hasten the resolution of warts and treat both benign and malignant neoplasms. Numerous clinical studies employing various methods to increase the cutaneous surface temperature, including: infrared radiation, radiofrequency, Nd:YAG laser, moxibustion, warm water immersion, ultrasound, and exothermic heat patches, have all yielded positive results. We published a proof-of-concept, open-label trial, representing the largest experience to date employing chemical reaction induced exothermic heat patches for the treatment of warts. Localized hyperthermia from all sources currently has a low level of evidence and strength of recommendation because of the lack of well-designed, sufficiently powered studies. 
Author Interviews, Cancer Research, HPV, Urology / 13.05.2019

MedicalResearch.com Interview with: [caption id="attachment_49147" align="alignleft" width="200"]Lael S. Reinstatler, MD, MPH.PGY 4 Urology ResidencyDartmouth Hitchcock Dr. Reinstatler[/caption] Lael S. Reinstatler, MD, MPH. PGY 4 Urology Residency Dartmouth Hitchcock MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Human Papillomavirus is an oncogenic virus associated with other genitourinary cancers including penile cancer. HPV is detectable in urine and in urethral swabs and it interacts with stratified squamous epithelium which lines the majority of the genitourinary tract. Prior research has identified HPV in bladder tumors but detection methods are inconsistent. In this study, we looked for an association with HPV serology (indicating prior HPV systemic exposure) and bladder cancer.
Author Interviews, HIV, HPV, Race/Ethnic Diversity, STD, Vaccine Studies / 08.04.2019

MedicalResearch.com Interview with: Perry N Halkitis, PhD, MS, MPH Dean and Professor Department of Urban-Global Public Health Rutgers Public Health  MedicalResearch.com: What is the background for this study? What are the main findings?  Response: The rate of human papillomavirus (HPV) infection is high among young minority gay, bisexual, and other men who have sex with men despite the availability of a vaccine that can prevent the infection, a Rutgers School of Public Health study found.
Author Interviews, BMJ, Cancer Research, HPV, OBGYNE, Sexual Health, Vaccine Studies / 05.04.2019

MedicalResearch.com Interview with: [caption id="attachment_48387" align="alignleft" width="112"]Dr. Tim PalmerHonorary Senior LecturerDepartment of PathologyUniversity of EdinburghEdinburgh, UK Dr. Palmer[/caption] Dr. Tim Palmer Honorary Senior Lecturer Department of Pathology University of Edinburgh Edinburgh, UK  MedicalResearch.com: What is the background for this study? What are the main findings?  Response: High risk HPV infection is the obligate cause of between 70 and 90% of cervical cancers, depending upon the country. The development of vaccines against the commonest hr-HPV types has the potential to reduce the burden of cervical cancer, especially in low and middle income countries that cannot afford screening programmes. Cervical cancer affects predominantly women in their 30s and is a major public health issue even in countries with well-established screening programmes. Scotland has had a successful immunisation programme since 2008, and women immunised at age 12 to13 have been screened since 2015. We can therefore demonstrate the effect of hr-HPV immunisation on the pre-invasive stages of cervical cancer.
AACR, Author Interviews, Cancer Research, HPV, University of Michigan, Vaccine Studies / 05.04.2019

MedicalResearch.com Interview with: [caption id="attachment_48381" align="alignleft" width="157"]Diane Harper, M.D., M.P.H., M.S.Professor of Family Medicine and Obstetrics and GynecologySenior Associate Director, Michigan Institute for Clinical and Health ResearchPhysician Director for Community Outreach, Engagement and Health Disparities,Rogel Cancer CenterMichigan Medicine Dr. Harper[/caption] Diane Harper, M.D., M.P.H., M.S. Professor of Family Medicine and Obstetrics and Gynecology Senior Associate Director, Michigan Institute for Clinical and Health Research Physician Director for Community Outreach, Engagement and Health Disparities, Rogel Cancer Center Michigan Medicine  MedicalResearch.com: What is the background for this study? Response: There is no current cure for women with HPV infection that has progressed to CIN 2/3 disease. The only treatment is for the diseased cervix, and does not eliminate the risk of another CIN 2/3 from the HPV infection 15-20 years later. This vaccine is made from a live virus that has 3 genes inserted:  human cytokine IL-2, and modified forms of HPV 16 E6 and E7 proteins. When the vaccine is injected subcutaneously, the proteins for HPV 16/E6 and E7 and the cytokine LI-2 proteins are made. These proteins trigger the immune response.  This is very different form imiquimod which is topical and not specific for HPV.
Author Interviews, BMJ, Cancer Research, HPV, OBGYNE / 13.02.2019

MedicalResearch.com Interview with: [caption id="attachment_47478" align="alignleft" width="200"]Matejka Rebolj, PhD King’s College London, London, UK Dr. Rebolj[/caption] Matejka Rebolj, PhD King’s College London, London, UK [caption id="attachment_47479" align="alignleft" width="139"]Henry Kitchener, MD FRCOG FRCS University of Manchester, Manchester, UK Dr. Kitchener[/caption]   Professor Henry Kitchener, MD FRCOG FRCS University of Manchester, Manchester, UK   MedicalResearch.com: What is the background for this study? Response: We now have reliable and affordable technologies to detect human papillomavirus (HPV), a virus which is universally accepted as the cause of cervical cancer. Various large trials confirmed that cervical screening could be improved by replacing the smear (cytology) test that has been in use for decades, with HPV testing. Many countries are now making the switch. In England, this is planned for the end of 2019. To test how to run HPV testing within the English National Health Service, a pilot was initiated in 2013 in six screening laboratories. We also wanted to determine whether the encouraging findings from the trials could be translated to everyday practice. This is important not only because we will be using different HPV tests, but also because women undergoing screening in trials are much more selected than those who are invited to population-based screening. 
Author Interviews, Cancer Research, HPV, Infections / 25.01.2019

MedicalResearch.com Interview with: [caption id="attachment_47138" align="alignleft" width="151"]Prof. J. (Hans) Berkhof PhD Vrije Universiteit Amsterdam  Prof. Berkhof[/caption] Prof. J. (Hans) Berkhof PhD Vrije Universiteit Amsterdam  MedicalResearch.com: What is the background for this study? What are the main findings?  Response: In most countries, the Pap test is used for cervical cancer screening but recently several countries have switched from Pap testing to HPV testing. Like the Pap test, the HPV test requires a cervical sample to be taken by a clinician. Vaginal self-sampling is also used, but only in underscreened women. We know that self-sampling increases screening participation in underscreened women and it is likely that many women that attend screening also prefer self-sampling if it had been offered to them. We studied whether an HPV self-sampling test is an accurate alternative to a regular HPV test in women invited for routine screening. We randomized about 14,000 women, invited for screening, to self-sampling or clinician-sampling. Women with a positive HPV test result also received the other HPV test. We found that the HPV self-sampling test yielded similar performance as the regular HPV test for detection of cervical pre-cancerous lesions (CIN3 and CIN2). 
Author Interviews, Cancer Research, HPV, JAMA, OBGYNE / 13.10.2018

MedicalResearch.com Interview with: [caption id="attachment_45199" align="alignleft" width="160"]Megan Clarke, PhD, MHS Cancer Prevention Fellow Clinical Genetics Branch Division of Cancer Epidemiology & Genetics National Cancer Institute Rockville, MD 20892 Dr. Clarke[/caption] Megan Clarke, PhD, MHS Cancer Prevention Fellow Clinical Genetics Branch Division of Cancer Epidemiology & Genetics National Cancer Institute Rockville, MD 20892  MedicalResearch.com: What is the background for this study?
  • Infection with high-risk human papillomavirus (hrHPV) is the primary cause of cervical cancer. While hrHPV infection is common, most infections are benign and clear on their own without causing cervical cancer. However, some women develop persistent hrHPV infections and are at risk for cervical cancer and its precursors (i.e., precancer).
  • The United States Preventative Services Task Force recommends screening every 3 years with cervical cytology (i.e. Pap) alone, every 5 years with hrHPV testing alone, or with a combination of hrHPV testing and cytology (co-testing) for women aged 30 to 65 years.
  • Screening with hrHPV testing is highly sensitive for detecting cervical precancer but requires additional triage tests to identify HPV-positive women at high-risk of developing cancer who should undergo colposcopy (visualization of the cervix) and biopsy from those at low-risk who can be safely monitored.
  • Currently, Pap cytology is recommended as a triage test for women testing HPV-positive, but this approach requires frequent re-testing at short intervals because the risk of cervical precancer is not low enough in HPV-positive women who test cytology negative to provide long-term reassurance against future risk. In most settings, women who test HPV-positive, cytology-negative are referred to repeat screening within one year.
  • The p16/Ki-67 dual stain assay is a molecular test that measures two specific proteins, p16 that is strongly linked with hrHPV infection, and Ki-67, a marker of cell proliferation that is common in precancers and cancers.
  • Studies have shown that the dual stain test has greater accuracy for detecting cervical precancers in HPV-positive women compared with cytology.
  • In order to determine the optimal screening intervals for the dual stain test, long-term prospective studies are needed to determine how long HPV-positive women who test dual stain negative can be safely reassured of a low precancer risk.
Author Interviews, HIV, HPV, PLoS, Sexual Health / 09.10.2018

MedicalResearch.com Interview with: [caption id="attachment_45122" align="alignleft" width="128"]Brandon Brown, MPH, PhD Associate Professor Center for Healthy Communities Department of Social Medicine, Population and Public Health UCR School of Medicine Riverside, CA  Dr. Brown[/caption] Brandon Brown, MPH, PhD Associate Professor Center for Healthy Communities Department of Social Medicine, Population and Public Health UCR School of Medicine Riverside, CA MedicalResearch.com: What is the background for this study? What are the main findings?  Response: The authors have been working in Lima, Peru on HIV-related projects for over 17 years. This particular study arose out of interest from our main community collaborator and the only gay men’s health NGO in Lima, Epicentro Salud . The NGO noticed that one of the main health issues among their clients was genital warts. When we learned this, we applied for funding through the Merck Investigator Initiated Studies Program to conduct a study examining the link between genital warts and incident HIV infection. [caption id="attachment_45123" align="alignleft" width="400"]The relationship between anogenital HPV types and incident HIV infection among men who have sex with men and transgender women in Lima, Peru The relationship between anogenital HPV types and incident HIV infection among men who have sex with men and transgender women in Lima, Peru[/caption] Although most studies have shown a general link between HPV and HIV co-infection, our findings illustrate the strong relationship between individual HPV types and HIV infection. Specifically, individuals in our study with any HPV type, more than one HPV type, or high-risk HPV were more likely to acquire HIV.
Author Interviews, Cancer Research, HPV, UCLA / 28.09.2018

MedicalResearch.com Interview with: [caption id="attachment_44899" align="alignleft" width="200"]Manon Eckhardt, PhD Gladstone Institutes Quantitative BioSciences Institute University of California San Francisco  Dr. Manon Eckhardt[/caption] Manon Eckhardt, PhD Gladstone Institutes The Quantitative Biosciences Institute University of California San Francisco  MedicalResearch.com: What is the background for this study? What are the main findings? Response: Infection with Human Papillomavirus (HPV) causes 5% of all cancers worldwide, including cervical cancer and an increasing number of head and neck cancers. Most cancers are caused by mutations in genes, leading to the production of malfunctioning proteins that result in unconstrained cell division. However, certain viruses like HPV can cause cancer without introducing mutations. In this study, we compared cancers of the same type (i.e. head and neck) that are caused by either mutation or virus infection to identify important processes that are dysregulated in both subsets. We hypothesized that identifying which proteins the virus binds can lead the way to prioritize which of the proteins and cellular processes (pathways) that are affected in cancer cells are most important. To do this, we identified the complete set of human proteins that interact with HPV. We next determined genes that were more frequently mutated in non-viral cancers, and combined both data sets. The proteins we find to be both binding to HPV and mutated in non-viral cancers will be potential targets for new, more specific drug development, and help better understand the development of head and neck cancer. From the many pathways we identified in this study, we highlighted two pathways with further mechanistic studies: the oxidative stress response, which helps cancer cells survive, as well as a pathway that allows the cancer to spread to other parts of the body.
Author Interviews, Cancer Research, Cost of Health Care, ENT, HPV, JAMA, Surgical Research / 18.09.2018

MedicalResearch.com Interview with: [caption id="attachment_44611" align="alignleft" width="133"]Richard B. Cannon, MD Division of Otolaryngology–Head and Neck Surgery School of Medicine University of Utah, Salt Lake City  Dr. Cannon[/caption] Richard B. Cannon, MD Division of Otolaryngology–Head and Neck Surgery School of Medicine University of Utah, Salt Lake City  MedicalResearch.com: What is the background for this study? What are the main findings?  Response: The Patient Protection and Affordable Care Act (ACA) is a nationwide effort to reduce the number of uninsured individuals in the United States and increase access to health care. This legislation is commonly debated and objective data is needed to evaluate its impact.  As a head and neck cancer surgeon, I sought to evaluate how the ACA had specifically influenced my patients.  Main findings below:     MedicalResearch.com: What should readers take away from your report? Response: This population-based study found an increase in the percentage of patients enrolled in Medicaid and private insurance and a large decrease in the rates of uninsured patients after implementation of the Patient Protection and Affordable Care Act (ACA).  This change was only seen in states that adopted the Medicaid expansion in 2014. The decrease in the rate of uninsured patients was significant, 6.2% before versus 3.0% after. Patients who were uninsured prior to the Patient Protection and Affordable Care Act had poorer survival outcomes.
Author Interviews, Cancer Research, ENT, HPV / 25.07.2018

MedicalResearch.com Interview with: [caption id="attachment_43416" align="alignleft" width="200"]Eric Adjei Boakye, PhD, MA Saint Louis University Center for Health Outcomes Research (SLUCOR) St. Louis, Missouri Dr. Boakye[/caption] Eric Adjei PhD, MA Saint Louis University Center for Health Outcomes Research (SLUCOR) St. Louis, Missouri  MedicalResearch.com: What is the background for this study? What are the main findings? Response: Survivors of head and neck cancer (HNC) develop second primary cancers (SPCs) at a higher rate than most common cancers. This is concerning because the number of HNC survivors are increasing due to advancements in treatment and technology. Patients whose head and neck cancer was caused by smoking and alcohol are different than those whose HNC were caused by human papillomavirus (HPV). We therefore used data from 2000-2014 National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) 18 database to examine if the incidence and the type of SPC that patients with smoking-related HNC develop were different from those from HPV-related head and neck cancer. First, independent of group of HNC (HPV-related or not), we found that SPCs among survivors of head and neck cancer were high, with about 1-in-8 patients developing an SPC. Additionally, irrespective of whether the index . head and neck cancer was from smoking-related or HPV-related, the majority of SPCs were second malignancies in head and neck region (e.g. tongue, gum, mouth floor etc), lung and esophagus. However, we observed different incidence rates between the two groups. Patients with smoking-related head and neck cancer developed SPCs at a higher rate (14%) than those with HPV-related HNC (10%).